Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck KGaA continues focus on strengthening pipeline with external innovation, says CFO on drug trials
Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.
FierceBiotech8h
Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Germany’s Merck Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...
Yale Daily News18h
Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...
FiercePharma1d
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Merck KGaA Earnings Growth Beats Expectations
Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...